Literature DB >> 23314445

Thiamine and spinocerebellar ataxia type 2.

Antonio Costantini1, Maria Immacolata Pala, Marco Colangeli, Serena Savelli.   

Abstract

Spinocerebellar ataxia type 2 is a genetic disorder characterised by the degeneration of the cerebellum, its connections and degeneration in brainstem areas. Some observations indicate that high doses of thiamine may lead to the partial regression of the symptoms. One patient was under rehabilitative treatment from June 2011 to July 2012. We assessed the level of fatigue using the Fatigue Severity Scale. We performed the Scale for Assessment and Rating of Ataxia and Robertson Profile for Dysarthria (Italian version). Thiamine and thiamine pyrophosphate levels in the blood were within the healthy reference range. We started a parenteral therapy with 100 mg intramuscular every 7 days. The therapy led to a partial regression of fatigue within a few days. After about 3 months, a discreet improvement of motor symptoms especially in speech was observed. The symptoms could derive from a focal thiamine deficiency that could determine a selective neuronal loss.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23314445      PMCID: PMC3604288          DOI: 10.1136/bcr-2012-007302

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  13 in total

1.  Pharmacokinetics of high-dose oral thiamine hydrochloride in healthy subjects.

Authors:  Howard A Smithline; Michael Donnino; David J Greenblatt
Journal:  BMC Clin Pharmacol       Date:  2012-02-04

2.  Mutations in a thiamine-transporter gene and Wernicke's-like encephalopathy.

Authors:  Satoshi Kono; Hiroaki Miyajima; Kenichi Yoshida; Akashi Togawa; Kentaro Shirakawa; Hitoshi Suzuki
Journal:  N Engl J Med       Date:  2009-04-23       Impact factor: 91.245

3.  Thiamin contents of cerebrospinal fluid, plasma and erythrocytes in cerebellar ataxias.

Authors:  M Poloni; P Mazzarello; U Laforenza; C Caramella; C Patrini
Journal:  Eur Neurol       Date:  1992       Impact factor: 1.710

4.  The modulation of Amyotrophic Lateral Sclerosis risk by ataxin-2 intermediate polyglutamine expansions is a specific effect.

Authors:  Suzana Gispert; Alexander Kurz; Stefan Waibel; Peter Bauer; Inga Liepelt; Christof Geisen; Aaron D Gitler; Tim Becker; Markus Weber; Daniela Berg; Peter M Andersen; Rejko Krüger; Olaf Riess; Albert C Ludolph; Georg Auburger
Journal:  Neurobiol Dis       Date:  2011-08-25       Impact factor: 5.996

Review 5.  Modeling neurodegenerative disease pathophysiology in thiamine deficiency: consequences of impaired oxidative metabolism.

Authors:  Shivraj S Jhala; Alan S Hazell
Journal:  Neurochem Int       Date:  2010-12-03       Impact factor: 3.921

6.  Differentiation of SCA2 from MSA-C using proton magnetic resonance spectroscopic imaging.

Authors:  Sylvia M Boesch; Christian Wolf; Klaus Seppi; Stephan Felber; Gregor K Wenning; Michael Schocke
Journal:  J Magn Reson Imaging       Date:  2007-03       Impact factor: 4.813

7.  Fatigue in spinocerebellar ataxia: patient self-assessment of an early and disabling symptom.

Authors:  Esther Brusse; Marjolein G J Brusse-Keizer; Hugo J Duivenvoorden; John C van Swieten
Journal:  Neurology       Date:  2011-03-15       Impact factor: 9.910

8.  Intrafamilial variability of Parkinson phenotype in SCAs: novel cases due to SCA2 and SCA3 expansions.

Authors:  M P Socal; V E Emmel; C R M Rieder; A Hilbig; M L Saraiva-Pereira; L B Jardim
Journal:  Parkinsonism Relat Disord       Date:  2008-11-05       Impact factor: 4.891

9.  Cerebellar alpha-ketoglutarate dehydrogenase activity is reduced in spinocerebellar ataxia type 1.

Authors:  F Mastrogiacomo; S J Kish
Journal:  Ann Neurol       Date:  1994-05       Impact factor: 10.422

10.  A review of the biochemistry, metabolism and clinical benefits of thiamin(e) and its derivatives.

Authors:  Derrick Lonsdale
Journal:  Evid Based Complement Alternat Med       Date:  2006-03       Impact factor: 2.629

View more
  5 in total

1.  High dose thiamine improves fatigue in multiple sclerosis.

Authors:  Antonio Costantini; Agostino Nappo; Maria Immacolata Pala; Antonietta Zappone
Journal:  BMJ Case Rep       Date:  2013-07-16

2.  High-dose thiamine improves the symptoms of fibromyalgia.

Authors:  Antonio Costantini; Maria Immacolata Pala; Silvia Tundo; Pietro Matteucci
Journal:  BMJ Case Rep       Date:  2013-05-20

3.  High-dose thiamine improves the symptoms of Friedreich's ataxia.

Authors:  Antonio Costantini; Rafaela Giorgi; Sonia D'Agostino; Maria Immacolata Pala
Journal:  BMJ Case Rep       Date:  2013-05-22

4.  High-dose thiamine as initial treatment for Parkinson's disease.

Authors:  Antonio Costantini; Maria Immacolata Pala; Laura Compagnoni; Marco Colangeli
Journal:  BMJ Case Rep       Date:  2013-08-28

5.  Can long-term thiamine treatment improve the clinical outcomes of myotonic dystrophy type 1?

Authors:  Antonio Costantini; Erika Trevi; Maria Immacolata Pala; Roberto Fancellu
Journal:  Neural Regen Res       Date:  2016-09       Impact factor: 5.135

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.